Central Nervous System: Occasionally, dizziness, headache and fatigue may occur. These symptoms are commonly mild and especially occur in the initial therapy. Rarely, hallucination, oviposition, depression, sleep disorder, incubus and psychosis may occur.
Cardiovascular System: Serious side effects eg, high-degree bradycardia and complete AV block and cardiac failure. Cardiac function test should be regularly performed. If those symptoms appear, appropriate treatment should be instituted to reduce dose or discontinue administration.
When taking carvedilol initially, increasing dose or suddenly standing up, blood pressure may be rarely remarkably low. Loss of consciousness may occur with symptoms eg, dizziness and blurred eye vision.
Frequently, pulse frequency may be reduced and rarely, extremity frigidity may occur. These symptoms may be worse in patients with intermittent claudication, Raynaud's disease, angina, edema and Prinzmetal's angina.
Dizziness may frequently occur in patients with cardiac failure, edema of variant nidus and size (especially in case of dosage increase) aggravation of AV block and cardiac failure may rarely occur.
Kidney: Systemic vascular disorder may occur or renal function may be worse or rarely, renal failure may occur in patients with impaired renal function. Acute renal failure and renal abnormalities have been reported in patients with heart failure who also suffered from diffuse vascular disease and/or renal impairment.
Respiratory System: Resistance of respiratory tract may be increased. Dyspnea, asthmatic attack and stuffy nose may rarely occur in patients with bronchospasms.
Gastrointestinal System: Nausea, diarrhea, abdominal pain, vomiting and constipation may rarely occur.
Skin: Urticaria, pruritus and lichen planus-like reaction have been reported. Allergic exanthema may rarely occur. Drugs having β-blocking activity may cause psoriasis vulgaris, aggravate symptom of this disease or cause psoriasis eruption.
Hematology: Change in liver function indicator (eg, serum transaminases), thrombocytopenia and leukopenia have been rarely reported.
Metabolic: Due to the β-blocking properties, it is also possible for latent diabetes mellitus to be manifested, manifested diabetes to be aggravated and blood glucose counter-regulation to be inhibited. Hypercholesterolemia, weight increase and hyperglycemia in patients with preexisting diabetes mellitus may occur in patients with heart function failure.
Hepatic: Liver function abnormalities, reversible on stopping treatment with carvedilol, have been reported rarely.
Others: Frequently, pain in the extremities, rarely, disorder of sensation (paresthesia), disturbed vision, eye irritation, dryness of the mouth, disturbances of micturition and sexual impotence may occur.